Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD).

SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...

Vyome Holdings, Inc. ("Vyome") (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for ...

The U.S. FDA has granted orphan drug designation to HCB101, an investigational immunotherapy, for the treatment of gastric cancer.

Rilzabrutinib is an investigational, oral reversible Bruton tyrosine kinase inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to rilzabrutinib for the treatment of ...

Aug. 1, 2005 — Europe has approved orphan drugs pegylated arginine deiminase for the treatment of hepatocellular carcinoma, soluble yeast beta-1,3/1,6-glucan for the prophylaxis of mucositis due to ...

(TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration ...

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges ...